Skip main navigation

Association Between Achieved Low-Density Lipoprotein Cholesterol Levels and Long-Term Cardiovascular and Safety Outcomes: An Analysis of FOURIER-OLE

Originally published 2023;147:1192–1203


Low-density lipoprotein cholesterol (LDL-C) is a well-established risk factor for atherosclerotic cardiovascular disease. However, the optimal achieved LDL-C level with regard to efficacy and safety in the long term remains unknown.


In FOURIER (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk), 27 564 patients with stable atherosclerotic cardiovascular disease were randomized to evolocumab versus placebo, with a median follow-up of 2.2 years. In the open-label extension (FOURIER-OLE), 6635 of these patients were transitioned to open-label evolocumab regardless of initial treatment allocation in the parent trial and were followed for an additional median of 5 years. In this prespecified analysis, we examined the relationship between achieved LDL-C levels (an average of the first 2 LDL-C levels measured) in FOURIER-OLE (available in 6559 patients) and the incidence of subsequent cardiovascular and safety outcomes. We also performed sensitivity analyses evaluating cardiovascular and safety outcomes in the entire FOURIER and FOURIER-OLE patient population. Multivariable modeling was used to adjust for baseline factors associated with achieved LDL-C levels.


In FOURIER-OLE, 1604 (24%), 2627 (40%), 1031 (16%), 486 (7%), and 811 (12%) patients achieved LDL-C levels of <20, 20 to <40, 40 to <55, 55 to <70, and ≥70 mg/dL, respectively. There was a monotonic relationship between lower achieved LDL-C levels—down to very low levels <20 mg/dL—and a lower risk of the primary efficacy end point (composite of cardiovascular death, myocardial infarction, stroke, hospital admission for unstable angina or coronary revascularization) and the key secondary efficacy end point (composite of cardiovascular death, myocardial infarction, or stroke) that persisted after multivariable adjustment (adjusted Ptrend<0.0001 for each end points). No statistically significant associations existed in the primary analyses between lower achieved LDL-C levels and increased risk of the safety outcomes (serious adverse events, new or recurrent cancer, cataract-related adverse events, hemorrhagic stroke, new-onset diabetes, neurocognitive adverse events, muscle-related events, or noncardiovascular death). Similar findings were noted in the entire FOURIER and FOURIER-OLE cohort up to a maximum follow-up of 8.6 years.


In patients with atherosclerotic cardiovascular disease, long-term achievement of lower LDL-C levels, down to <20 mg/dL (<0.5 mmol/L), was associated with a lower risk of cardiovascular outcomes with no significant safety concerns.


URL:; Unique identifier: NCT01764633.


Supplemental Material, the podcast, and transcript are available with this article at

Continuing medical education (CME) credit is available for this article. Go to to take the quiz.

For Sources of Funding and Disclosures, see page 1201.

Circulation is available at

Correspondence to: Marc S. Sabatine, MD, MPH, TIMI Study Group, Brigham and Women’s Hospital, Harvard Medical School, 60 Fenwood Road, 7th Floor, Boston, MA 02115. Email


  • 1. Michos ED, McEvoy JW, Blumenthal RS. Lipid management for the prevention of atherosclerotic cardiovascular disease.N Engl J Med. 2019; 381:1557–1567. doi: 10.1056/NEJMra1806939CrossrefMedlineGoogle Scholar
  • 2. Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, Hegele RA, Krauss RM, Raal FJ, Schunkert H, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease: 1: evidence from genetic, epidemiologic, and clinical studies: a consensus statement from the European Atherosclerosis Society Consensus Panel.Eur Heart J. 2017; 38:2459–2472. doi: 10.1093/eurheartj/ehx144CrossrefMedlineGoogle Scholar
  • 3. Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, Kuder JF, Wang H, Liu T, Wasserman SM, et al, FOURIER Steering Committee and Investigators. Evolocumab and clinical outcomes in patients with cardiovascular disease.N Engl J Med. 2017; 376:1713–1722. doi: 10.1056/nejmoa1615664CrossrefMedlineGoogle Scholar
  • 4. O’Donoghue ML, Giugliano RP, Wiviott SD, Atar D, Keech A, Kuder JF, Im K, Murphy SA, Flores-Arredondo JH, López JAG, et al. Long-term evolocumab in patients with established atherosclerotic cardiovascular disease.Circulation. 2022; 146:1109–1119. doi: 10.1161/CIRCULATIONAHA.122.061620LinkGoogle Scholar
  • 5. Giugliano RP, Pedersen TR, Park J-G, De Ferrari GM, Gaciong ZA, Ceska R, Toth K, Gouni-Berthold I, Lopez-Miranda J, Schiele F, et al. Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial.Lancet. 2017; 390:1962–1971. doi: 10.1016/S0140-6736(17)32290-0CrossrefMedlineGoogle Scholar
  • 6. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins.Lancet. 2005; 366:1267–1278. doi: 10.1016/S0140-6736(05)67394-1CrossrefMedlineGoogle Scholar
  • 7. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.Circulation. 2002; 106:3143–3421.LinkGoogle Scholar
  • 8. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Joyal SV, Hill KA, Pfeffer MA, Skene AM. Intensive versus moderate lipid lowering with statins after acute coronary syndromes.N Engl J Med. 2004; 350:1495–1504. doi: 10.1056/nejmoa040583CrossrefMedlineGoogle Scholar
  • 9. de Lemos JA, Blazing MA, Wiviott SD, Lewis EF, Fox KAA, White HD, Rouleau J-L, Pedersen TR, Gardner LH, Mukherjee R, et al; for the A to Z Investigators. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial.JAMA. 2004; 292:1307–1316. doi: 10.1001/jama.292.11.1307CrossrefMedlineGoogle Scholar
  • 10. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart J-C, Gotto AM, Greten H, Kastelein JJP, Shepherd J, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease.N Engl J Med. 2005; 352:1425–1435. doi: 10.1056/NEJMoa050461CrossrefMedlineGoogle Scholar
  • 11. Armitage J, Bowman L, Wallendszus K, Bulbulia R, Rahimi K, Haynes R, Parish S, Peto R, Collins R; Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) Collaborative GroupStudy of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) Collaborative Group. Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial.Lancet. 2010; 376:1658–1669. doi: 10.1016/S0140-6736(10)60310-8CrossrefMedlineGoogle Scholar
  • 12. Pedersen TR, Faergeman O, Kastelein JJP, Olsson AG, Tikkanen MJ, Holme I, Larsen ML, Bendiksen FS, Lindahl C, Szarek M, et al; Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial.JAMA. 2005; 294:2437–2445. doi: 10.1001/jama.294.19.2437CrossrefMedlineGoogle Scholar
  • 13. Grundy SM, Cleeman JI, Merz CNB, Brewer HB, Clark LT, Hunninghake DB, Pasternak RC, Smith SC, Stone NJ; National Heart, Lung, and Blood Institute. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.Circulation. 2004; 110:227–239. doi: 10.1161/01.CIR.0000133317.49796.0ELinkGoogle Scholar
  • 14. Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, Darius H, Lewis BS, Ophuis TO, Jukema JW, et al. Ezetimibe added to statin therapy after acute coronary syndromes.N Engl J Med. 2015; 372:2387–2397. doi: 10.1056/nejmoa1410489CrossrefMedlineGoogle Scholar
  • 15. Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Goodman SG, Hanotin C, Harrington RA, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome.N Engl J Med. 2018; 379:2097–2107. doi: 10.1056/nejmoa1801174CrossrefMedlineGoogle Scholar
  • 16. Wiviott SD, Cannon CP, Morrow DA, Ray KK, Pfeffer MA, Braunwald E; PROVE IT-TIMI 22 Investigators. Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy: a PROVE IT-TIMI 22 substudy.J Am Coll Cardiol. 2005; 46:1411–1416. doi: 10.1016/j.jacc.2005.04.064CrossrefMedlineGoogle Scholar
  • 17. Giugliano RP, Wiviott SD, Blazing MA, De Ferrari GM, Park J-G, Murphy SA, White JA, Tershakovec AM, Cannon CP, Braunwald E. Long-term safety and efficacy of achieving very low levels of low-density lipoprotein cholesterol: a prespecified analysis of the IMPROVE-IT trial.JAMA Cardiol. 2017; 2:547–555. doi: 10.1001/jamacardio.2017.0083CrossrefMedlineGoogle Scholar
  • 18. Patti G, Spinoni EG, Grisafi L, Mehran R, Mennuni M. Safety and efficacy of very low LDL-cholesterol intensive lowering: a meta-analysis and meta-regression of randomized trials.Eur Heart J. 2022;pvac049. doi: 10.1093/ehjcvp/pvac049CrossrefGoogle Scholar
  • 19. Feng Q, Wei W-Q, Chung CP, Levinson RT, Sundermann AC, Mosley JD, Bastarache L, Ferguson JF, Cox NJ, Roden DM, et al. Relationship between very low low-density lipoprotein cholesterol concentrations not due to statin therapy and risk of type 2 diabetes: a US-based cross-sectional observational study using electronic health records.PLoS Med. 2018; 15:e1002642. doi: 10.1371/journal.pmed.1002642CrossrefMedlineGoogle Scholar
  • 20. Andersson C, Lyass A, Larson MG, Robins SJ, Vasan RS. Low-density-lipoprotein cholesterol concentrations and risk of incident diabetes: epidemiological and genetic insights from the Framingham Heart Study.Diabetologia. 2015; 58:2774–2780. doi: 10.1007/s00125-015-3762-xCrossrefMedlineGoogle Scholar
  • 21. Cohen JC, Boerwinkle E, Mosley TH, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease.N Engl J Med. 2006; 354:1264–1272. doi: 10.1056/NEJMoa054013CrossrefMedlineGoogle Scholar
  • 22. Zhao Z, Tuakli-Wosornu Y, Lagace TA, Kinch L, Grishin NV, Horton JD, Cohen JC, Hobbs HH. Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote.Am J Hum Genet. 2006; 79:514–523. doi: 10.1086/507488CrossrefMedlineGoogle Scholar
  • 23. Hooper AJ, Marais AD, Tanyanyiwa DM, Burnett JR. The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population.Atherosclerosis. 2007; 193:445–448. doi: 10.1016/j.atherosclerosis.2006.08.039CrossrefMedlineGoogle Scholar
  • 24. Langsted A, Nordestgaard BG, Benn M, Tybjærg-Hansen A, Kamstrup PR. PCSK9 R46L loss-of-function mutation reduces lipoprotein(a), LDL cholesterol, and risk of aortic valve stenosis.J Clin Endocrinol Metab. 2016; 101:3281–3287. doi: 10.1210/jc.2016-1206CrossrefMedlineGoogle Scholar
  • 25. Lee CJ, Lee Y, Park S, Kang S-M, Jang Y, Lee JH, Lee S-H. Rare and common variants of APOB and PCSK9 in Korean patients with extremely low low-density lipoprotein-cholesterol levels.PLoS One. 2017; 12:e0186446. doi: 10.1371/journal.pone.0186446CrossrefMedlineGoogle Scholar
  • 26. Kudo T, Sasaki K, Tada H. Familial hypobetalipoproteinemia caused by homozygous loss-of-function mutations in PCSK9: a case report.J Clin Lipidol. 2022; 16:596–600. 10.1016/j.jacl.2022.07.010CrossrefMedlineGoogle Scholar
  • 27. Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, Benetos A, Biffi A, Boavida J-M, Capodanno D, et al; ESC National Cardiac Societies. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice: developed by the Task Force for cardiovascular disease prevention in clinical practice with representatives of the European Society of Cardiology and 12 medical societies With the special contribution of the European Association of Preventive Cardiology (EAPC).Eur Heart J. 2021; 42:3227–3337. doi: 10.1093/eurheartj/ehab484CrossrefMedlineGoogle Scholar
  • 28. Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, Chapman MJ, De Backer GG, Delgado V, Ference BA, et al; ESC Scientific Document Group. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS).Eur Heart J. 2020; 41:111–188. doi: 10.1093/eurheartj/ehz455CrossrefMedlineGoogle Scholar
  • 29. Lloyd-Jones DM, Morris PB, Ballantyne CM, Birtcher KK, Covington AM, DePalma SM, Minissian MB, Orringer CE, Smith SC, Waring AA, et al; Writing Committee. 2022 ACC expert consensus decision pathway on the role of nonstatin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk.J Am Coll Cardiol. 2022; 80:1366–1418. doi: 10.1016/j.jacc.2022.07.006CrossrefMedlineGoogle Scholar